Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 32Multiple Myeloma 23Leukemia, Myeloid, Acute 23Lymphoma 17Colorectal Neoplasms 16Breast Neoplasms 14Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Triple Negative Breast Neoplasms 10Sarcoma 9Prostatic Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 9Burkitt Lymphoma 9Ovarian Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, T-Cell 7Glioma 7Endometrial Neoplasms 7Neuroblastoma 6Melanoma 6Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Myeloproliferative Disorders 5Lymphoma, Follicular 5Fallopian Tube Neoplasms 5Cholangiocarcinoma 5Central Nervous System Neoplasms 5

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Biopsy × 30 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡